Exact Sciences Under Scrutiny for Shareholder Fairness
The Ademi Firm has initiated an investigation into Exact Sciences Corporation (NASDAQ: EXAS) regarding possible breaches of fiduciary duty related to its recent partnership with Abbott. This inquiry arises from concerns that the transaction may not be in the best interest of public shareholders.
Understanding the Transaction Details
As part of the arrangement, shareholders of Exact Sciences will receive $105 per share in cash. This totals an equity value nearing $21 billion, along with an estimated enterprise valuation of approximately $23 billion. Notably, insiders and executives of Exact Sciences are poised to acquire significant advantages from this change of control.
Investigating Potential Irregularities
Our investigation focuses on whether the Exact Sciences board of directors has adequately protected the interests of all shareholders in light of the terms set forth in the transaction agreement. Importantly, the agreement may unduly restrict any competing offers by imposing a hefty penalty should Exact Sciences consider an alternative bid.
Fulfilling Shareholder Rights
At the Ademi Firm, we dedicate ourselves to advocating for shareholder rights, especially concerning buyouts, mergers, and the legal obligations of corporate boards. We emphasize that legal representation is available for shareholders looking into this matter, and there is no cost or obligation to pursue this inquiry.
Contact Information
If you wish to learn more about how this could affect your investment or to join our investigation, please reach out via the following contact methods: Guri Ademi at Ademi & Fruchter LLP offers support and can be reached toll-free at (866) 264-3995 or via fax at (414) 482-8001.
Frequently Asked Questions
What is the Ademi Firm investigating regarding Exact Sciences?
The Ademi Firm is investigating whether Exact Sciences is providing a fair deal to its public shareholders in light of its transaction with Abbott.
How much are Exact Sciences shareholders set to receive?
Shareholders will receive $105 per share in cash, equating to an equity value of around $21 billion.
What concerns does the investigation raise about the transaction?
There are concerns regarding potential breaches of fiduciary duty and limitations imposed on competing bids for Exact Sciences.
Who can shareholders contact for more information?
Shareholders can contact Guri Ademi at Ademi & Fruchter LLP for further details regarding the investigation.
Is there any cost for shareholders to join the investigation?
No, there is no cost or obligation for shareholders wishing to learn more or participate in the investigation.